Analytical Data
-
Gene name
SLC38A2
- Application
-
Alternative Names
ATA2; KIAA1382; SAT2; SNAT2
-
Species
Human
-
Source
HEK293
-
Tag
His;MBP;Flag
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96QD8-1
-
Expression Region
K2-H506
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC38A2, a member of the SLC38 family of sodium-coupled amino acid transporters, plays a crucial role in the transport of neutral amino acids across cellular membranes. This transporter is highly expressed in various tissues, particularly in the brain, where it is implicated in maintaining amino acid homeostasis and neurotransmitter synthesis. Dysregulation of SLC38A2 has been associated with several neurological disorders, highlighting its importance in neurobiology. Research on the recombinant SLC38A2 protein involves the expression and characterization of this transporter to understand its functional properties, substrate specificity, and transport mechanisms. By generating a recombinant form of SLC38A2, scientists can investigate the effects of specific mutations and identify potential pharmacological targets for the treatment of diseases linked to amino acid transport deficiencies. Additionally, studying the structure-function relationships of SLC38A2 will advance our understanding of membrane transport processes and pave the way for developing novel therapeutic strategies aimed at modulating amino acid transport in various pathological conditions.
